Basal cell carcinoma pathogenesis and therapy involving hedgehog signaling and beyond

• Published in: Molecular carcinogenesis Vol. 56; no. 12; pp. 2543 - 2557
• Main Authors: Bakshi, Anshika, Chaudhary, Sandeep C., Rana, Mehtab, Elmets, Craig A., Athar, Mohammad
• Format: Journal Article
• Language: English
• Published: United States Wiley Subscription Services, Inc 01-12-2017
• Subjects: Basal cell carcinoma; BCC; Carcinoma, Basal Cell - genetics; Carcinoma, Basal Cell - pathology; Carcinoma, Basal Cell - therapy; Chemotherapy; Cilia - metabolism; Disease Progression; hedgehog; Hedgehog protein; Hedgehog Proteins - genetics; Hedgehog Proteins - metabolism; Humans; Immunotherapy; Information processing; Inhibitors; Lesions; Metastases; MicroRNAs; miRNA; Models, Genetic; Mutation; Neoplasia; Nevus; Pathogenesis; photodynamic immunotherapy; Photodynamic therapy; Proteins; Signal transduction; Signal Transduction - genetics; Skin cancer; Skin Neoplasms - genetics; Skin Neoplasms - pathology; Skin Neoplasms - therapy; therapeutics; TOR protein; Wnt protein; therapeutics; BCC; hedgehog; photodynamic immunotherapy
• DOI: 10.1002/mc.22690
• EISSN: 1098-2744
• ISSN: 0899-1987

Basal cell carcinoma (BCC) of the skin is driven by aberrant hedgehog signaling. Thus blocking this signaling pathway by small molecules such as vismodegib inhibits tumor growth. Primary cilium in the epidermal cells plays an integral role in the processing of hedgehog signaling‐related proteins. Recent genomic studies point to the involvement of additional genetic mutations that might be associated with the development of BCCs, suggesting significance of other signaling pathways, such as WNT, NOTCH, mTOR, and Hippo, aside from hedgehog in the pathogenesis of this human neoplasm. Some of these pathways could be regulated by noncoding microRNA. Altered microRNA expression profile is recognized with the progression of these lesions. Stopping treatment with Smoothened (SMO) inhibitors often leads to tumor reoccurrence in the patients with basal cell nevus syndrome, who develop 10‐100 of BCCs. In addition, the initial effectiveness of these SMO inhibitors is impaired due to the onset of mutations in the drug‐binding domain of SMO. These data point to a need to develop strategies to overcome tumor recurrence and resistance and to enhance efficacy by developing novel single agent‐based or multiple agents‐based combinatorial approaches. Immunotherapy and photodynamic therapy could be additional successful approaches particularly if developed in combination with chemotherapy for inoperable and metastatic BCCs.